Login / Signup

Initiation and interruption in intravenous bisphosphonate therapy among patients with multiple myeloma in the United States.

Leah J McGrathRohini K HernandezRobert OvermanDiane ReamsAlexander LiedeM Alan BrookhartElizabeth O'Donnell
Published in: Cancer medicine (2018)
Many patients with NDMM do not initiate IV BPs, particularly those with renal complications. Interruptions of IV BPs were common.
Keyphrases
  • multiple myeloma
  • risk factors
  • stem cells
  • low dose
  • mesenchymal stem cells
  • smoking cessation